These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23289445)

  • 1. Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target.
    Smetana K; André S; Kaltner H; Kopitz J; Gabius HJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):379-92. PubMed ID: 23289445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling galectin-1 as a novel therapeutic target for cancer.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
    Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Galectins in Tumors and in Clinical Immunotherapy.
    Chou FC; Chen HY; Kuo CC; Sytwu HK
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.
    Rapoport EM; André S; Kurmyshkina OV; Pochechueva TV; Severov VV; Pazynina GV; Gabius HJ; Bovin NV
    Glycobiology; 2008 Apr; 18(4):315-24. PubMed ID: 18256179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of structural and functional overlap/divergence of five proto-type galectins by analysis of the growth-regulatory interaction with ganglioside GM1 in silico and in vitro on human neuroblastoma cells.
    André S; Kaltner H; Lensch M; Russwurm R; Siebert HC; Fallsehr C; Tajkhorshid E; Heck AJ; von Knebel Doeberitz M; Gabius HJ; Kopitz J
    Int J Cancer; 2005 Mar; 114(1):46-57. PubMed ID: 15523676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory roles of galectins in the immune response.
    Liu FT
    Int Arch Allergy Immunol; 2005 Apr; 136(4):385-400. PubMed ID: 15775687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design-functionality relationships for adhesion/growth-regulatory galectins.
    Ludwig AK; Michalak M; Xiao Q; Gilles U; Medrano FJ; Ma H; FitzGerald FG; Hasley WD; Melendez-Davila A; Liu M; Rahimi K; Kostina NY; Rodriguez-Emmenegger C; Möller M; Lindner I; Kaltner H; Cudic M; Reusch D; Kopitz J; Romero A; Oscarson S; Klein ML; Gabius HJ; Percec V
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2837-2842. PubMed ID: 30718416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target?
    Romero A; Gabius HJ
    Expert Opin Ther Targets; 2019 Oct; 23(10):819-828. PubMed ID: 31575307
    [No Abstract]   [Full Text] [Related]  

  • 9. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
    Sioud M; Mobergslien A; Boudabous A; Fløisand Y
    Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
    Sörme P; Kahl-Knutsson B; Huflejt M; Nilsson UJ; Leffler H
    Anal Biochem; 2004 Nov; 334(1):36-47. PubMed ID: 15464951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Galectins, a class of unconventional lectins].
    Advedissian T; Deshayes F; Poirier F; Grandjean C; Viguier M
    Med Sci (Paris); 2015 May; 31(5):499-505. PubMed ID: 26059300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor suppressor p16 INK4a: Downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model.
    Sanchez-Ruderisch H; Fischer C; Detjen KM; Welzel M; Wimmel A; Manning JC; André S; Gabius HJ
    FEBS J; 2010 Sep; 277(17):3552-63. PubMed ID: 20695889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-1 inhibitors and their potential therapeutic applications: a patent review.
    Blanchard H; Bum-Erdene K; Bohari MH; Yu X
    Expert Opin Ther Pat; 2016 May; 26(5):537-54. PubMed ID: 26950805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
    Moiseeva EV; Rapoport EM; Bovin NV; Miroshnikov AI; Chaadaeva AV; Krasilshschikova MS; Bojenko VK; Bijleveld C; van Dijk JE; Den Otter W
    Breast Cancer Res Treat; 2005 Jun; 91(3):227-41. PubMed ID: 15952056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings.
    Laderach DJ; Compagno D; Toscano MA; Croci DO; Dergan-Dylon S; Salatino M; Rabinovich GA
    IUBMB Life; 2010 Jan; 62(1):1-13. PubMed ID: 20014236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present).
    Sethi A; Sanam S; Alvala R; Alvala M
    Expert Opin Ther Pat; 2021 Aug; 31(8):709-721. PubMed ID: 33749494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor galectinology: insights into the complex network of a family of endogenous lectins.
    Lahm H; André S; Hoeflich A; Kaltner H; Siebert HC; Sordat B; von der Lieth CW; Wolf E; Gabius HJ
    Glycoconj J; 2004; 20(4):227-38. PubMed ID: 15115907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation and histochemical localization of galectin-1 and galectin-1-reactive glycoconjugates in fetal development of bovine organs.
    Kaltner H; Lips KS; Reuter G; Lippert S; Sinowatz F; Gabius HJ
    Histol Histopathol; 1997 Oct; 12(4):945-60. PubMed ID: 9302557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Galectins in Multiple Myeloma.
    Storti P; Marchica V; Giuliani N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells.
    Ohannesian DW; Lotan D; Thomas P; Jessup JM; Fukuda M; Gabius HJ; Lotan R
    Cancer Res; 1995 May; 55(10):2191-9. PubMed ID: 7743523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.